Between January 2014 and February 2019, 280 patients with locally advanced invasive breast cancer were screened and 259 eligible patients were enrolled in the analysis, consisting of 155 HER2-negative (66 HER2-zero and 89 HER2-low) and 104 HER2-positive patients (Supplementary Figure S1). Here, ERBB2 is linked to invasive breast carcinoma.